All In Biotech

Drug Trial Radar · NCT06764485

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 960 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

960

Planned (sponsor's estimate)

Start

Mar 13, 2025

Primary completion

Sep 12, 2027

Study completion Jan 19, 2029

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jan 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.

Conditions

  • Metastatic Castration-resistant Prostate Cancer

Interventions

  • BMS-986365Drug

    Specified dose on specified days

  • EnzalutamideDrug

    Specified dose on specified days

  • AbirateroneDrug

    Specified dose on specified days

  • DocetaxelDrug

    Specified dose on specified days

  • Predinsone/PrednisoloneDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radiographic progression-free survival (rPFS) by blinded independent central review (BICR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (soft tissue) and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) (bone) criteriaTime frame: Up to 4 years

Locations

227 sites in 26 countries. Site status is shown where the registry gives one.

  • Local Institution - 0330

    Birmingham, Alabama

  • Local Institution - 0329

    Gilbert, Arizona

  • Local Institution - 0370

    Anaheim, California

  • Local Institution - 0015

    La Jolla, California

  • Local Institution - 0224

    Los Alamitos, California

  • Local Institution - 0016

    San Francisco, California

  • Local Institution - 0411

    San Francisco, California

  • Local Institution - 0238

    Aurora, Colorado

  • Local Institution - 0294

    Denver, Colorado

  • Local Institution - 0419

    Lakewood, Colorado

  • Local Institution - 0413

    Washington D.C., District of Columbia

  • Local Institution - 0426

    Lakeland, Florida

  • Local Institution - 0077

    Athens, Georgia

  • Local Institution - 0048

    Chicago, Illinois

  • Local Institution - 0331

    Westwood, Kansas

  • Local Institution - 0060

    Wichita, Kansas

  • Local Institution - 0054

    Baltimore, Maryland

  • Local Institution - 0019

    Baltimore, Maryland

  • Local Institution - 0344

    Frederick, Maryland

  • Local Institution - 0429

    Sewell, New Jersey

  • Local Institution - 0081

    Albuquerque, New Mexico

  • Local Institution - 0334

    Albuquerque, New Mexico

  • Local Institution - 0197

    Buffalo, New York

  • Local Institution - 0412

    Mineola, New York

  • Local Institution - 0069

    New York, New York

  • Local Institution - 0076

    New York, New York

  • Local Institution - 0085

    New York, New York

  • Local Institution - 0071

    New York, New York

  • Local Institution - 0225

    Syracuse, New York

  • Local Institution - 0056

    Columbus, Ohio

  • Local Institution - 0067

    Portland, Oregon

  • Local Institution - 0416

    Portland, Oregon

  • Local Institution - 0345

    Philadelphia, Pennsylvania

  • Local Institution - 0414

    Philadelphia, Pennsylvania

  • Local Institution - 0057

    Philadelphia, Pennsylvania

  • Local Institution - 0349

    Willow Grove, Pennsylvania

  • Local Institution - 0055

    Charleston, South Carolina

  • Local Institution - 0079

    Myrtle Beach, South Carolina

  • Local Institution - 0335

    Nashville, Tennessee

  • Local Institution - 0018

    Austin, Texas

Showing 40 of 227 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.